

# INDEX

---

- abdominal pain, pre-eclampsia 197
- abortion, subsequent pre-eclampsia 194
- ACE inhibitors 20–3
  - diabetic nephropathy 6–9
  - dialysis patients 33
  - dosage 22
  - effects, TRAS diagnosis 171–2
  - plasma renin activity 20
  - pregnancy hypertension 212–14
  - renal artery occlusion 16
  - renal function effects 90
- acebutolol, pregnancy hypertension 207–8
- adrenergic neurone-blockers,
  - hypertension/renal failure 18, 20
- aldosterone levels, post-transplant 182
- amlodipine 25
- anaemia, haemorrhagic retinopathy 51, 52, 53
- analgesic nephropathy, hypertension 2, 5–6
- angiography, digital subtraction (DSA)
  - contrast medium, renal damage risk 88, 130
  - RAS 13–14, 87–9, 119–20
  - TRAS 169–70
  - see also* intra-arterial/intravenous DSA (IADSA; IVDSA)
- angioplasty, percutaneous transluminal (PTA)
  - adjunctive medical therapy 127
  - antithrombotic measures 127
  - blood pressure response 132–3, 136
  - complications 129–31, 144–6
  - intravenous DSA 170
  - MRC studies 139–51
    - technical outcome 142–4
  - outcome 137, 138–9
  - patient preparation 125
  - patient selection 139–42
  - procedure 126
  - RAS 13, 14, 15–16, 104
    - recurrence 127, 132
  - renovascular hypertension 125–37
  - successful, mechanism/radiology 126–7
  - technical success, determinants 127–9
  - TRAS 138–9
    - management 173–4
- angiotensin II
  - afferent arteriolar tone 90
  - pregnancy, ACE inhibitors 212–13
- antihypertensive therapy
  - dialysis patients 32–3
  - renal risks 16–18
- antihypertensives
  - cerebral blood flow, autoregulation effects 54, 55, 202–3
  - parenteral 58, 59
  - placental blood flow effects 202–3
  - pregnancy hypertension 203–14
- aorta, dissecting aneurysms 63
- aortoiliac endarterectomy, and renal bypass 97
- aortorenal bypass grafts
  - operative mortality 97
  - RAS 96–7, 100
  - results 104–5
- arteriovenous fistulae, intrarenal, post-transplant biopsy 179–80
- arteritis 81
  - hypertension association 18
- atenolol 23, 24
  - metabolism 24
  - pregnancy hypertension 208
  - uncomplicated MHT 54, 55
- atheroma
  - patient age 83–4
  - post-PTA RAS recurrence 132

## INDEX

- atheroma – *cont.*
  - PTA and renal function 135, 136–7
  - RAS 14, 15–16
    - intervention therapy 15–16
    - mortality 15
    - PTA complications 129–30
    - risk factors 16
  - renal arteries 80–1
- autotransplantation, renal
  - disadvantages 99
  - RAS 98–9
- azathioprine
  - post-transplant renal function effects 177
  - transplant hypertension 178–9
  
- bacteriuria, renovascular hypertension 83
- balloon angioplasty, TRAS 101–3
- berry aneurysms 10
- beta-adrenoceptor antagonists 23–4
  - diabetic nephropathy 8
  - pregnancy hypertension 205–9
  - renal artery occlusion 16
- bethanidine, hypertension/renal failure 20
- biopsy, post-transplant, arteriovenous fistulae
  - 179–80
- blood pressure
  - pre/post-transplant correlation 161
  - PTA response 132–6
- blood volume, post-transplant 182
- body weight
  - increase, PIH 96
  - transplant hypertension 175
- breathlessness, malignant hypertension 49
- bruits, renal hypertension 83
  
- calcium antagonists 24–5
  - diabetic nephropathy 8
  - disadvantages 25
  - pregnancy hypertension 210
- captopril 20–3
  - adverse effects 20–2
  - diabetic nephropathy 6
  - DPTA scintigraphy effects 117–18
  - elimination 22
  - fetal effects 213
  - GFR effects 171–2
  - hypotensive response, RAS 124
  - long-term response, surgery outcome 90
  - nephrectomy patient selection 165
  - pregnancy contraindication 214
  - pregnancy hypertension 212–14
  - prostaglandin release 213
  - TRAS hypertension 175
  - uterine blood flow effects 212–13
- cardiac index, post-transplant ‘idiopathic’
  - hypertension 180–1
- cardioselective beta-blockers, diabetic nephropathy 23
- catecholamines, myocardial
  - infarction/hypertension 60
- cerebral blood flow, autoregulation, blood pressure fall effects 54, 55, 203–4
- cerebral haemorrhage, hypertensive
  - encephalopathy differentiation 49–50
- cerebral infarction, boundary zone 54
- children
  - hypertension risk, maternal hypertension 197
  - transplant hypertension, prevalence 160
- CHP *see* pregnancy
- cigarette smoking
  - intravascular coagulation 47
  - MHT development 46–7
- clonidine
  - methyldopa comparisons 212
  - pregnancy hypertension 211–12
- coagulation
  - abnormalities, MHT 47–8
  - disseminated intravascular (DIC), PIH 195
  - intravascular, smoking 47
- Conn’s syndrome, malignant hypertension 45
- continuous ambulatory peritoneal dialysis (CAPD) 32
- contraceptives, oral, MHT development 47–8
- contrast media, complications 88, 130
- creatinine, plasma levels
  - ACE inhibitor effects 17–18
  - renal function 7
- cyclosporin, transplant hypertension 178–9
  
- debrisoquine, hypertension/renal failure 20
- diabetic nephropathy
  - antihypertensive therapy 6–9
  - cardioselective beta-blockers 23
- dialysis
  - antihypertensive therapy 32–3
  - drug removal, unwanted 32
- diazepam, intravenous, seizures 59
- diazoxide 25–6
  - eclampsia 201
  - intravenous, hypertensive encephalopathy 59
  - protein binding 26
- digital subtraction angiography *see* angiography
- disseminated intravascular coagulation (DIC), PIH 195
- diuretics 26–7
  - pregnancy hypertension 204
  - see also various types*

## INDEX

- donor kidneys, hypertension association 167  
 DTPA scintigraphy, RAS 117–18
- echo-Doppler velocimetry  
 RAS 118–19  
 TRAS 170
- eclampsia  
 clinical aspects 199–200  
 labour effects 200  
 prognosis 201  
 seizures 194  
 treatment 200–1  
*see also* pre-eclampsia
- embolism, renal artery stenosis 81
- embolization, percutaneous intravascular,  
 transplant hypertension 166, 180
- enalapril 20–3  
 adverse effects 21  
 elimination 22  
 pregnancy contraindication 214  
 TRAS hypertension 175
- encephalopathy, transplant hypertension 161  
*see also* diabetic encephalopathy;  
 hypertensive encephalopathy
- endarterectomy, transaortic renal, RAS 95–6
- end-stage renal disease *see* ESRD
- EPH gestosis 193
- ESRD  
 analgesic nephropathy 5–6  
 glomerulonephritis 68–9  
 antihypertensive therapy 9  
 hypertensive nephropathy 3–4  
 interstitial nephritis 69  
 renal artery stenosis 80
- essential hypertension  
 definition 159  
 malignant phase 70–1  
 MHT development 45  
 pre-eclampsia as risk 197  
 renovascular hypertension differences 83
- ethinyloestradiol, MHT association 47
- extracellular fluid volume, salt intake/blood  
 pressure 182
- fibrinoid arteriolar necrosis, malignant  
 hypertension 42, 43, 44
- fibromuscular dysplasia  
 intervention outcome 121  
 patient age 84  
 PTA and renal function 135, 136–7  
 RAS 14, 15, 81–2  
 PTA and blood pressure response 133–6,  
 149, 150  
 PTA complications 130  
 string of beads sign 82
- fibromuscular dysplasia – *cont.*  
 types 81–2  
 fluid retention, renal function impairment 185
- ganglion-blocking agents, pregnancy  
 contraindication 214
- gastrointestinal effects, malignant  
 hypertension 50
- GFR  
 ACE inhibitor effects 17  
 measurement, EDTA/DTPA 7
- glomerulonephritis  
 ESRD 68–9  
 antihypertensive therapy 9  
 hypertension 2, 4  
 pretransplant, transplant hypertension 163
- glucocorticoids, dosage, transplant  
 hypertension relationships 175–6
- glyceryl trinitrate 28
- guanethidine, hypertension/renal failure 20
- haemolytic anaemia, microangiopathic, MHT  
 42, 44, 50
- headache  
 malignant hypertension 48  
 pre-eclampsia 196
- heart failure, hypertensive 57
- high-ceiling diuretics 27
- hydralazine 28–9  
 diabetic nephropathy 8  
 eclampsia 121  
 intravenous, hypertensive encephalopathy  
 59  
 metabolism 29  
 parenteral, MHT/renal failure 56  
 pregnancy hypertension 209–10
- hydronephrosis, antihypertensive therapy 10
- hyperaldosteronism, secondary, MHT 50
- hyperparathyroidism, primary 10
- hypertension  
 ‘accelerated’ 42  
 definition difficulties 159  
 ‘idiopathic’, post-transplant 180–4  
 racial aspects 3  
 renal function/prognosis 2–3  
 severity, renal failure correlation 3  
*see also various types*
- hypertensive donors, recipient transplant  
 hypertension 167
- hypertensive encephalopathy 57, 59–60  
 cerebral haemorrhage differentiation 49–50
- hypokalaemia, renovascular hypertension 83
- hypotension, first-dose  
 ACE inhibitors 21–2  
 methyldopa 30

## INDEX

- hypoxia, focal, retinal changes 52
- infarction, renal, hypertension 12
- intra-arterial digital subtraction angiography (IADSA) 89
- intracranial pressure, raised, MHT
  - retinopathy differences 51, 52, 53
- intrauterine growth retardation
  - captopril-associated 213
  - methyl dopa 211
- intravenous digital subtraction angiography (IVDSA)
  - disadvantages 88
  - RAS 87–9
- IVU *see* urography, intravenous
- ketanserin, pregnancy hypertension 212
- labetalol
  - intravenous, hypertensive encephalopathy 59
  - phaeochromocytoma 61–2
  - pregnancy hypertension 208–9
- left ventricular hypertrophy, MHT 49
- loop diuretics 27
- lupus syndrome, hydralazine-induced 28, 29
- magnesium sulphate
  - calcium antagonist potentiation 210
  - eclampsia 200–1
  - PIH convulsions 199
- malignant hypertension (MHT) 41–78
  - arteriolar 'sausage strings' 44
  - clinical features 48–50
  - diagnostic criteria 42–3
  - epidemiology 44–5
  - fibrinoid necrosis 42, 43, 44
  - initial management 52, 54–60
  - pathogenesis 44
  - prognosis 63–5
  - racial aspects 45, 46
  - renal failure 55–7, 68
  - uncomplicated 54–5
  - underlying causes 45–8
  - WHO criteria 42
  - see also* retinopathy, hypertensive
- methyl dopa 29–30
  - clonidine comparisons 212
  - diabetic nephropathy 8–9
  - pregnancy hypertension 211
- metoprolol 23–4
  - metabolism 24
  - pregnancy hypertension 207
- MHT *see* malignant hypertension
- minoxidil 30
  - renal function effects 90
  - TRAS hypertension 174
- myocardial infarction and hypertension 60
- transplant recipients 160
- neonates, labetalol side-effects 209
- nephrectomy, bilateral
  - indications 165–6
  - morbidity/mortality 164
  - pretransplant 164–6
  - response prediction 164–5
  - transplant hypertension 163
  - results, renovascular hypertension 104
- nephritis, interstitial 11–12
  - ESRD 69
  - hypertension 2, 5
- nephrotensin, transplant hypertension 163
- nicardipine 24–5
- nifedipine 24–5
  - pregnancy hypertension 210
  - renal failure induction 25
  - uncomplicated MHT 54, 56
- nitroprusside 30–1
  - dosage 59
  - hypertensive encephalopathy 59
  - intravenous
    - aortic dissections 63
    - phaeochromocytoma 62
    - renal function effects 90
- noradrenaline, plasma levels, post-transplant 181
- obesity, renovascular hypertension 83
- occlusion, renal artery 16
  - ACE inhibitors 22
- oliguric renal failure, malignant hypertension 42, 68
- oral contraceptives, MHT development 47–8
- oxprenolol, pregnancy hypertension 206
- papillary necrosis, renal 5
- papilloedema, malignant hypertension 42
- percutaneous renal ablation, transplant hypertension 166
- percutaneous transluminal angioplasty *see* angioplasty
- peritoneal dialysis, continuous ambulatory (CAPD) 32
- phaeochromocytoma 61–2
  - diagnostic clues 62
- phenoxybenzamine, phaeochromocytoma 61, 62
- phentolamine, phaeochromocytoma 62

## INDEX

- PIH *see* pregnancy-induced hypertension
- placental blood flow, antihypertensive drug effects 202–3
- placental function, hydralazine effects 210
- polycystic kidney disease, antihypertensive therapy 10–11
- potassium-sparing diuretics 27
- PRA *see* renin, plasma activity (PRA)
- prazosin 31–2
  - diabetic nephropathy 9
- prednisone, dose, and transplant hypertension 176
- pre-eclampsia 193
  - associated disorders 193
  - body weight increase 196
  - post-abortion 194
  - see also* eclampsia
- pregnancy, chronic hypertension (CHP) 202–14
- pregnancy-induced hypertension (PIH) 193–201
  - clinical aspects 196–7
  - complications 194
  - diagnosis 193–4
  - immunological mechanisms 194
  - pathogenesis 194–6
  - prevention 198
  - prognosis 197
  - treatment 198–9
- primiparae/multiparae, pre-eclampsia differences 194–5
- propranolol 23–4
  - fetal effects 206
  - intravenous, aortic dissections 63
  - metabolism 24
  - phaeochromocytoma 61, 62
  - pregnancy hypertension 205–6
- prostacyclin, PIH 195–6
- prostaglandin E<sub>2</sub>, uterine, pregnancy 212
- prostaglandins, PIH 195–6
- proteinuria
  - captopril-induced 21
  - pre-eclampsia 197
- PTA *see* angioplasty, percutaneous transluminal
- pyelonephritis 11–12
  - hypertension 2
- radioisotope renography
  - RAS 115–16, 118
  - renovascular diseases/hypertension 85
- RAS *see* stenosis
- renal artery, reimplantation, RAS 98
- renal artery stenosis (RAS) *see* stenosis; transplant renal artery stenosis
- renal blood flow, transplant hypertension 183
- renal failure
  - ACE inhibitors 21–2
  - hypertension 2
    - severity correlation 3
  - malignant hypertension 49, 55–7
  - prevention, PTA 136, 137
- renal function
  - MHT treatment effects 65, 68–71
  - preservation, PTA 136, 137, 149, 150
- renin
  - release, RAS 13, 14
  - uterine, pregnancy 212
- renin, plasma activity (PRA)
  - ACE inhibitors 20
  - nephrectomized transplant recipients 181, 183
  - post-transplant 181–2
  - RAS 90–1
  - transplant hypertension 162, 163–4, 171
  - TRAS 171, 184
- renin, renal vein 165
  - hypertension, Vaughan criteria 123
  - pyelonephritis/interstitial nephritis 11
  - RAS evaluation 122–4
  - TRAS 171
- renin–angiotensin system, renovascular hypertension 91
- renovascular disease, hypertension 12–18
  - hypertension difference 84
  - see also* stenosis, renal artery (RAS); transplant renal artery stenosis
- renovascular hypertension
  - aortorenal grafts, results 104–5
  - clinical aspects 83–4, 113–15
  - detection 114–25
  - essential hypertension differences 83
  - intervention response, predictive tests 120–5
  - investigation method choice 93–4
  - nephrectomy, results 104
  - pathophysiology 79–82
  - patient age 83
  - prevalence 79–80
  - surgery, patient selection 91–4
  - see also* stenosis, renal artery (RAS)
- renovascular trauma 12
- retinal vein, central, occlusion, MHT
  - retinopathy differences 51, 52, 53
- retinopathy
  - hypertensive, differential diagnosis 50–1, 52
  - ischaemic, malignant hypertension 49, 51
  - MHT treatment effects 65, 66, 67

## INDEX

- saralsin, renal vascular hypertension
    - assessment 124
  - scintigraphy, renal, RAS 117, 118
  - scleroderma, renal crises 18, 62
    - ACE inhibitors 22
  - serotonin, myocardial infarction/
    - hypertension 60
  - small kidney, unilateral 12
  - sodium
    - exchangeable
      - transplant hypertension 176, 182
      - TRAS 184
    - intake, transplant hypertension 177–8
    - potassium ATPase, inhibition, transplant hypertension 184
  - sodium nitroprusside *see* nitroprusside
  - splenorenal bypass, RAS 97
  - stenosis, renal artery (RAS) 12–14
    - antihypertensive drug therapy 16–18
    - associated disorders 80–1
    - bilateral, assessment 123–4
    - DSA 119–20
    - functional tests 90–1
    - hypertension-induced 3
    - insufficiency/hypertension 80–1
    - intravenous urography (IVU) 85–7
    - investigation planning 91–4
    - Oxford experience 99–103
    - pressure gradient measurement 122
    - radioisotope renography 85, 115–16, 118
    - surgery 94–103
      - outcome 14, 103–5
      - time course 13
    - ultrasonic/echo–Doppler studies 118–19
    - underlying disease 14
    - see also* transplant renal artery stenosis
  - stroke
    - and hypertension 60–1
    - subarachnoid haemorrhage 61
    - transplant recipients 160
  - subarachnoid haemorrhage, stroke 61
  - subintimal cellular proliferation, intralobar,
    - MHT 43, 44
  - systemic sclerosis, progressive 62
- Takayasu's disease 81
- thiazide diuretics 26–7
  - diabetic nephropathy 9
- thiocyanate, adverse effects 30–1
- thromboxane A<sub>2</sub>, PIH 195–6
- toxaemia of pregnancy 193
- transaortic renal endarterectomy, RAS 95–6
- transitional cell tumours, renal 5
- transplant hypertension 101–3
  - azathioprine 178–9
  - transplant hypertension – *cont.*
    - body weight 177
    - cyclosporin 178–9
    - definition 159
    - donor kidney 167
    - glucocorticoid dosage 175–6
    - and graft function 175
    - host kidney 162–4
    - pathogenesis 161–4
    - percutaneous renal ablation 166
    - plasma renin activity 162, 163–4, 171
    - prevalence 160
    - renal blood flow 183
    - renal vascular resistance 183
    - sodium intake 17–18
    - sodium/potassium ATPase inhibition 185
    - TRAS, medical treatment 174–5
  - transplant renal artery stenosis (TRAS) 162, 168–75
    - anatomical diagnosis 169–70
    - causes 168–9
    - clinical features 169
    - functional diagnosis 170–2
    - hypertension, pathophysiology 184–5
    - prevalence 168
    - PTA 173–4, 138–9
    - PTA outcome 138–9
    - PTA/surgery roles 174
    - surgery 173–4
    - treatment 172–5
    - types 138, 168
  - TRAS *see* transplant renal artery stenosis
- urography, intravenous (IVU)
  - bilateral lesions 86
  - diagnostic features 115, 116–17
  - RAS 85–7
  - sensitivity/specificity 86
- uropathy, obstructive, antihypertensive
  - therapy 10
- uteroplacental ischaemia, PIH 195–6
- vascular disease
  - hypertension role 161
  - risk factors 160
  - transplant recipients 160–1
- vascular resistance
  - peripheral, post-transplant 'idiopathic'
    - hypertension 180–1
  - renal, transplant hypertension 183
- Vaughan criteria, renal vein renin,
  - hypertension 123
- velocimetry, echo–Doppler
  - RAS 118–19

## INDEX

velocimetry – *cont.*

    TRAS 170

verapamil 24–5

vision, MHT treatment effects 65

visual disturbances

    malignant hypertension 48–9

    pre-eclampsia 196–7